Hoth Therapeutics, Inc. (HOTH)
After hours:
| Previous close | 0.8100 |
| Open | 0.9000 |
| Bid | 0.8029 x 100 |
| Ask | 0.8666 x 100 |
| Day's range | 0.8312 - 0.9000 |
| 52-week range | 0.7200 - 3.3700 |
| Volume | |
| Avg. volume | 696,969 |
| Market cap | 4.473M |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with LTS Therapy Systems, LLC ("LTS"), to develop and manufacture the HT-ALZ oral film prototype. HT-ALZ is being developed as a novel therapeutic solution for Alzheimer's Disease based on its exciting preclinical results released earlier this year. HT-ALZ's pre-clinical significance lies in its ability to restore cognitive functions and improve quality of life for subj
- PR Newswire
Hoth Therapeutics Expands Clinical Trial for Cancer Patients
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has received written approval from the GW University Hospital, UC Irvine and Northwell Health to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).
- PR Newswire
Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a joint development agreement with Wise Systems International SRL to leverage artificial intelligence utilizing the BioNeMo AI platform of Nvidia.
